-
Formononetin Protects Against Oxaliplatin Neurotoxicity
2026-08-18
The reference study identifies formononetin as a neuroprotective isoflavone that reduces oxaliplatin-induced oxidative stress and neuronal apoptosis through the Nrf2/HO-1 pathway. Its key translational contribution is showing that neuronal protection can be achieved without weakening oxaliplatin or paclitaxel anticancer activity in tumor-cell models, although protection against paclitaxel-associated neurite damage was limited.
-
Leucomycin (Kitasamycin): Designing Better Assays
2026-08-18
Leucomycin and kitasamycin are best understood as a composition-variable macrolide complex, not simply a single antibiotic. This guide shows how component biology, ribosomal targeting, uptake, and resistance should shape translational inhibition and bacterial growth assays.
-
Bestatin and Angiotensin Signaling in Rat Brain
2026-08-17
Harding and Felix used complementary aminopeptidase inhibitors, peptide analogs, and neuronal electrophysiology to test whether angiotensin II must be converted to angiotensin III before activating rat brain neurons. Their results support a conversion-dependent signaling model and provide a useful framework for interpreting Bestatin hydrochloride, also known as Ubenimex, in mechanistic research.
-
Hypoxia and Immunometabolism in Tumors
2026-08-17
This review integrates tumor hypoxia, metabolic reprogramming, and immune-cell dysfunction into a unified model of immunosuppressive tumor microenvironment development. Its practical value lies in showing why glucose and nutrient competition should be interpreted alongside oxygen gradients, HIF signaling, immune phenotypes, and therapeutic response.
-
Biotin-tyramide for TSA: Workflow & Troubleshooting
2026-08-16
Biotin-tyramide converts HRP activity into localized biotin deposition for sensitive fluorescence and chromogenic imaging in IHC and ISH. This guide connects practical TSA optimization with proximity-labeling lessons from a fission-yeast study while clearly separating validated findings from workflow recommendations.
-
Astrocytic GAT-3 Shapes Dentate Gyrus Memory
2026-08-15
The reference study identifies astrocytic GAT-3 as an active regulator of dentate gyrus synaptic transmission rather than merely a GABA clearance mechanism. By linking GAT-3 uptake to astrocytic calcium signaling, presynaptic GluN2B-containing NMDARs, and contextual fear memory, it provides a mechanistic framework for studying glia–neuron control of hippocampal function.
-
Baicalein: From 12-LOX to Assay Design
2026-08-14
Baicalein is more than a flavonoid compound for cancer research: it is a mechanistic probe whose solvent behavior, 12-LOX activity, and redox-sensitive phenotype must be interpreted together. This guide connects assay design with insights from recent chemotherapy-neurotoxicity research without conflating baicalein with formononetin.
-
BRCAness and Olaparib Sensitivity in Mesothelioma
2026-08-14
Borchert et al. linked homologous recombination repair gene-expression patterns with Olaparib susceptibility in malignant pleural mesothelioma models. Their results suggest that BAP1-associated BRCAness, particularly when combined with cisplatin, may identify a therapeutically relevant subgroup, while also highlighting the need for functional and prospective validation.
-
SLC2A5 Fructose Metabolism in Primary CNS Lymphoma
2026-08-13
A 2026 Advanced Science study uses single-cell RNA and B-cell receptor profiling to show how glucose-poor, hypoxic conditions in primary central nervous system lymphoma reshape tumor and immune-cell metabolism. The work identifies SLC2A5-mediated fructose uptake as a shared vulnerability in lymphoma cells and tumor-supportive macrophages, while offering a framework for validating these cell states with reproducible tissue and cell-based assays.
-
Native Protein Gel Electrophoresis with K4142
2026-08-13
This scenario-driven guide explains how native protein gel electrophoresis can complement cell viability, proliferation, and cytotoxicity assays. It outlines practical selection, preparation, optimization, and interpretation considerations for the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit (PI ≤ 7.0), SKU K4142.
-
CLCC1 and Herpesvirus Nuclear Egress
2026-08-12
A 2024 bioRxiv study identifies the host protein CLCC1 as an essential factor for membrane fusion during herpesvirus nuclear egress, a step that allows capsids to leave the nucleus after viral budding. Genetic loss of CLCC1 traps capsids in perinuclear vesicles, reduces viral production, and disrupts nuclear pore complex insertion, linking viral replication to a conserved mechanism of nuclear envelope morphogenesis.
-
GW 6471: PPARα Antagonist Workflow Guide
2026-08-12
GW 6471 provides a practical pharmacological complement to transcriptomics, histology, and PPARα knockdown when researchers need to test whether receptor signaling drives lipid or liver phenotypes. This guide translates a larval zebrafish PFHxS study into controlled workflows for cellular metabolism research, lipid homeostasis studies, and PPARα-related disease modeling.
-
2-Thio-dCTP Workflows for Precision DNA Studies
2026-08-11
2-Thio-dCTP enables controlled sulfur substitution during DNA synthesis, supporting polymerase selectivity testing, site-specific DNA modification, and DNA–protein interaction studies. This practical guide connects reagent handling and assay design with the SCP4 chromosome-stability findings while separating established evidence from assay-development recommendations.
-
Resazurin Assays for Translational Cancer Decisions
2026-08-11
Resazurin reduction is more than a viability readout: it is a decision point between phenotype and mechanism. This article examines how the Resazurin Cell Viability Assay Kit can support sensitive, scalable oncology studies while clarifying what metabolic signals can—and cannot—prove.
-
GW 6471: A PPARα Antagonist for Metabolic Research
2026-08-10
GW 6471 is a small-molecule PPARα antagonist used to interrogate PPARα transcriptional control in cellular metabolism research and lipid homeostasis studies. Product information reports an approximate IC50 of 0.24 μM, while zebrafish toxicology evidence supports pharmacological PPAR pathway inhibition as a tool for testing PFHxS-associated liver and lipid effects.